Sativex has been
developed, produced
and marketed by
GW Pharmaceuticals

World leaders
Image
icons

GW Pharmaceuticals
has established a world-
leading position in
cannabinoid science
and medicine

Our mission

To unlock the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials to improve the lives of seriously ill patients

Our achievements

The drive to find solutions for complex medical problems has led us to gain regulatory approval of world-first cannabis-based medicines1–3

Our future

GW Pharmaceuticals is committed to leveraging our experience, expertise and extensive body of research in cannabinoid science to treat other diseases where significant unmet need exists

 

References:
1. FDA. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy.www.fda.gov/news-events/pressannouncements/fda-approves-first-drugcomprised-active-ingredient-derived-marijuanatreat-rare-severe-forms (accessed February 2021).
2. EMA. Epidyolex. www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (accessed February 2021).
3. Patented Medicine Prices Review Board. Annual report 2006. http://www.pmprbcepmb.gc.ca/view.asp?ccid=905 (accessed February 2021).